{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:49:21Z","timestamp":1773053361878,"version":"3.50.1"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s13346-022-01256-w","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:03:41Z","timestamp":1667865821000},"page":"1322-1342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Multifunctional nanomedicine strategies to manage brain diseases"],"prefix":"10.1007","volume":"13","author":[{"given":"Paulo","family":"Faria","sequence":"first","affiliation":[]},{"given":"Catarina","family":"Pacheco","sequence":"additional","affiliation":[]},{"given":"Rui Pedro","family":"Moura","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-6974","authenticated-orcid":false,"given":"Cl\u00e1udia","family":"Martins","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"1256_CR1","doi-asserted-by":"crossref","unstructured":"Markowicz-Piasecka M, Markiewicz A, Dar\u0142ak P, Sikora J, Adla SK, Bagina S, et al. Current chemical, biological, and physiological views in the development of successful brain-targeted pharmaceutics. Neurotherapeutics. 2022.","DOI":"10.1007\/s13311-022-01228-5"},{"issue":"4","key":"1256_CR2","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1021\/acs.jmedchem.0c02145","volume":"64","author":"F Calzaferri","year":"2021","unstructured":"Calzaferri F, Narros-Fern\u00e1ndez P, de Pascual R, de Diego AMG, Nicke A, Egea J, et al. Synthesis and pharmacological evaluation of novel non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation. J Med Chem. 2021;64(4):2272\u201390.","journal-title":"J Med Chem"},{"key":"1256_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119491","volume":"224","author":"J Xie","year":"2019","unstructured":"Xie J, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224: 119491.","journal-title":"Biomaterials"},{"issue":"6","key":"1256_CR4","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.7150\/thno.21254","volume":"8","author":"X Dong","year":"2018","unstructured":"Dong X. Current strategies for brain drug delivery. Theranostics. 2018;8(6):1481\u201393.","journal-title":"Theranostics"},{"key":"1256_CR5","doi-asserted-by":"crossref","unstructured":"Pinheiro RGR, Coutinho AJ, Pinheiro M, Neves AR. Nanoparticles for targeted brain drug delivery: what do we know? Int J Mol Sci. 2021;22(21).","DOI":"10.3390\/ijms222111654"},{"issue":"9","key":"1256_CR6","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/s41593-021-00904-7","volume":"24","author":"S Schaeffer","year":"2021","unstructured":"Schaeffer S, Iadecola C. Revisiting the neurovascular unit. Nat Neurosci. 2021;24(9):1198\u2013209.","journal-title":"Nat Neurosci"},{"key":"1256_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2020.105794","volume":"125","author":"E van Leeuwen","year":"2020","unstructured":"van Leeuwen E, Hampton MB, Smyth LCD. Redox signalling and regulation of the blood-brain barrier. Int J Biochem Cell Biol. 2020;125: 105794.","journal-title":"Int J Biochem Cell Biol"},{"issue":"9","key":"1256_CR8","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s11095-007-9324-2","volume":"24","author":"WM Pardridge","year":"2007","unstructured":"Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24(9):1733\u201344.","journal-title":"Pharm Res"},{"issue":"1","key":"1256_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40005-017-0374-0","volume":"48","author":"D Ghosh","year":"2018","unstructured":"Ghosh D, Peng X, Leal J, Mohanty R. Peptides as drug delivery vehicles across biological barriers. J Pharm Investig. 2018;48(1):89\u2013111.","journal-title":"J Pharm Investig"},{"key":"1256_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.addr.2018.04.009","volume":"135","author":"Y Pan","year":"2018","unstructured":"Pan Y, Nicolazzo JA. Impact of aging, Alzheimer\u2019s disease and Parkinson\u2019s disease on the blood-brain barrier transport of therapeutics. Adv Drug Deliv Rev. 2018;135:62\u201374.","journal-title":"Adv Drug Deliv Rev"},{"key":"1256_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114115","volume":"182","author":"S Quader","year":"2022","unstructured":"Quader S, Kataoka K, Cabral H. Nanomedicine for brain cancer. Adv Drug Deliv Rev. 2022;182: 114115.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1256_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","volume":"20","author":"JN Sarkaria","year":"2017","unstructured":"Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Is the blood\u2013brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 2017;20(2):184\u201391.","journal-title":"Neuro Oncol"},{"issue":"6","key":"1256_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s13244-018-0661-y","volume":"9","author":"AT Kessler","year":"2018","unstructured":"Kessler AT, Bhatt AA. Brain tumour post-treatment imaging and treatment-related complications. Insights Imaging. 2018;9(6):1057\u201375.","journal-title":"Insights Imaging"},{"issue":"20","key":"1256_CR14","doi-asserted-by":"publisher","first-page":"7600","DOI":"10.3390\/ijms21207600","volume":"21","author":"X Dong","year":"2020","unstructured":"Dong X, Gao J, Su Y, Wang Z. Nanomedicine for ischemic stroke. Int J Mol Sci. 2020;21(20):7600.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1256_CR15","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2217\/nnm.14.206","volume":"10","author":"M Gregori","year":"2015","unstructured":"Gregori M, Masserini M, Mancini S. Nanomedicine for the treatment of Alzheimer\u2019s disease. Nanomedicine. 2015;10(7):1203\u201318.","journal-title":"Nanomedicine"},{"issue":"3","key":"1256_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/17425247.2019.1583205","volume":"16","author":"RP Moura","year":"2019","unstructured":"Moura RP, Martins C, Pinto S, Sousa F, Sarmento B. Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology. Expert Opin Drug Deliv. 2019;16(3):271\u201385.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"1256_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1152\/physrev.00050.2017","volume":"99","author":"MD Sweeney","year":"2019","unstructured":"Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21\u201378.","journal-title":"Physiol Rev"},{"issue":"8","key":"1256_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.tibtech.2008.04.005","volume":"26","author":"N Sanvicens","year":"2008","unstructured":"Sanvicens N, Marco MP. Multifunctional nanoparticles \u2013 properties and prospects for their use in human medicine. Trends Biotechnol. 2008;26(8):425\u201333.","journal-title":"Trends Biotechnol"},{"issue":"7","key":"1256_CR19","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1039\/C2CS15261D","volume":"41","author":"DE Lee","year":"2012","unstructured":"Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev. 2012;41(7):2656\u201372.","journal-title":"Chem Soc Rev"},{"issue":"8","key":"1256_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrn1728","volume":"6","author":"W L\u00f6scher","year":"2005","unstructured":"L\u00f6scher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6(8):591\u2013602.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"1256_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","volume":"2","author":"W L\u00f6scher","year":"2005","unstructured":"L\u00f6scher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005;2(1):86\u201398.","journal-title":"NeuroRx"},{"issue":"5","key":"1256_CR22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1517\/17425255.2016.1168804","volume":"12","author":"A Mahringer","year":"2016","unstructured":"Mahringer A, Fricker G. ABC transporters at the blood-brain barrier. Expert Opin Drug Metab Toxicol. 2016;12(5):499\u2013508.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1256_CR23","doi-asserted-by":"crossref","unstructured":"Gomez-Zepeda D, Taghi M, Scherrmann J-M, Decleves X, Menet M-C. ABC transporters at the blood\u2013brain interfaces, their study models, and drug delivery implications in gliomas. Pharmaceutics. 2020;12(1).","DOI":"10.3390\/pharmaceutics12010020"},{"key":"1256_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107554","volume":"213","author":"E Gil-Martins","year":"2020","unstructured":"Gil-Martins E, Barbosa DJ, Silva V, Remi\u00e3o F, Silva R. Dysfunction of ABC transporters at the blood-brain barrier: role in neurological disorders. Pharmacol Ther. 2020;213: 107554.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"1256_CR25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1046\/j.1471-4159.2003.02181.x","volume":"88","author":"IG Kirkinezos","year":"2004","unstructured":"Kirkinezos IG, Hernandez D, Bradley WG, Moraes CT. An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J Neurochem. 2004;88(4):821\u20136.","journal-title":"J Neurochem"},{"issue":"1","key":"1256_CR26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1471-4159.2007.04772.x","volume":"103","author":"A Milane","year":"2007","unstructured":"Milane A, Fernandez C, Vautier S, Bensimon G, Meininger V, Farinotti R. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier. J Neurochem. 2007;103(1):164\u201373.","journal-title":"J Neurochem"},{"issue":"3","key":"1256_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.neulet.2010.01.078","volume":"472","author":"A Milane","year":"2010","unstructured":"Milane A, Fernandez C, Dupuis L, Buyse M, Loeffler JP, Farinotti R, et al. P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. Neurosci Lett. 2010;472(3):166\u201370.","journal-title":"Neurosci Lett"},{"issue":"12","key":"1256_CR28","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/acn3.141","volume":"1","author":"MR Jablonski","year":"2014","unstructured":"Jablonski MR, Markandaiah SS, Jacob D, Meng NJ, Li K, Gennaro V, et al. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Ann Clin Transl Neurol. 2014;1(12):996\u20131005.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1256_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neulet.2008.12.061","volume":"452","author":"A Milane","year":"2009","unstructured":"Milane A, Vautier S, Chacun H, Meininger V, Bensimon G, Farinotti R, et al. Interactions between riluzole and ABCG2\/BCRP transporter. Neurosci Lett. 2009;452(1):12\u20136.","journal-title":"Neurosci Lett"},{"issue":"2","key":"1256_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1349-7006.2001.tb01084.x","volume":"92","author":"S Haga","year":"2001","unstructured":"Haga S, Hinoshita E, Ikezaki K, Fukui M, Scheffer GL, Uchiumi T, et al. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Jpn J Cancer Res. 2001;92(2):211\u20139.","journal-title":"Jpn J Cancer Res"},{"issue":"16","key":"1256_CR31","first-page":"5114","volume":"63","author":"JM Gallo","year":"2003","unstructured":"Gallo JM, Li S, Guo P, Reed K, Ma J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res. 2003;63(16):5114\u20137.","journal-title":"Cancer Res"},{"key":"1256_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.phrs.2015.09.003","volume":"102","author":"A Kort","year":"2015","unstructured":"Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP\/ABCB1) and breast cancer resistance protein (BCRP\/ABCG2). Pharmacol Res. 2015;102:200\u20137.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1256_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.canlet.2015.07.013","volume":"367","author":"JL Munoz","year":"2015","unstructured":"Munoz JL, Walker ND, Scotto KW, Rameshwar P. Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Lett. 2015;367(1):69\u201375.","journal-title":"Cancer Lett"},{"issue":"7","key":"1256_CR34","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.neo.2018.05.001","volume":"20","author":"MC de Gooijer","year":"2018","unstructured":"de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, et al. Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2. Neoplasia. 2018;20(7):710\u201320.","journal-title":"Neoplasia"},{"issue":"8","key":"1256_CR35","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1021\/acs.molpharmaceut.9b00018","volume":"16","author":"IC Salaroglio","year":"2019","unstructured":"Salaroglio IC, Abate C, Rolando B, Battaglia L, Gazzano E, Colombino E, et al. Validation of thiosemicarbazone compounds as P-glycoprotein inhibitors in human primary brain-blood barrier and glioblastoma stem cells. Mol Pharm. 2019;16(8):3361\u201373.","journal-title":"Mol Pharm"},{"issue":"3","key":"1256_CR36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.stem.2009.01.007","volume":"4","author":"AM Bleau","year":"2009","unstructured":"Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al. PTEN\/PI3K\/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4(3):226\u201335.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1256_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1528-1157.1995.tb01657.x","volume":"36","author":"DM Tishler","year":"1995","unstructured":"Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 1995;36(1):1\u20136.","journal-title":"Epilepsia"},{"key":"1256_CR38","doi-asserted-by":"crossref","unstructured":"Moerman L, wyffels L, Slaets D, Raedt R, Boon P, De Vos F. Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with 11C-desmethylloperamide.\u00a0Epilepsy Res. 2011;94(1):18\u201325.","DOI":"10.1016\/j.eplepsyres.2010.12.013"},{"issue":"5","key":"1256_CR39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S1525-5050(02)00511-5","volume":"3","author":"GJ Sills","year":"2002","unstructured":"Sills GJ, Kwan P, Butler E, de Lange EC, van den Berg DJ, Brodie MJ. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav. 2002;3(5):427\u201332.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1256_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.nbd.2006.06.014","volume":"24","author":"C Brandt","year":"2006","unstructured":"Brandt C, Bethmann K, Gastens AM, L\u00f6scher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis. 2006;24(1):202\u201311.","journal-title":"Neurobiol Dis"},{"issue":"10","key":"1256_CR41","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/j.1528-1167.2005.00250.x","volume":"46","author":"EA van Vliet","year":"2005","unstructured":"van Vliet EA, Redeker S, Aronica E, Edelbroek PM, Gorter JA. Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia. 2005;46(10):1569\u201380.","journal-title":"Epilepsia"},{"key":"1256_CR42","doi-asserted-by":"crossref","unstructured":"Bazhanova ED, Kozlov AA, Litovchenko AV. Mechanisms of drug resistance in the pathogenesis of epilepsy: role of neuroinflammation. A literature review. Brain Sci. 2021;11(5).","DOI":"10.3390\/brainsci11050663"},{"issue":"6","key":"1256_CR43","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/j.1528-1167.2005.54904.x","volume":"46","author":"D Schmidt","year":"2005","unstructured":"Schmidt D, L\u00f6scher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia. 2005;46(6):858\u201377.","journal-title":"Epilepsia"},{"issue":"1","key":"1256_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neulet.2005.04.020","volume":"383","author":"M Uhr","year":"2005","unstructured":"Uhr M, Ebinger M, Rosenhagen MC, Grauer MT. The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neurosci Lett. 2005;383(1):73\u20136.","journal-title":"Neurosci Lett"},{"issue":"10","key":"1256_CR45","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714\u201326.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1256_CR46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jconrel.2012.04.034","volume":"161","author":"R Nieto Montesinos","year":"2012","unstructured":"Nieto Montesinos R, B\u00e9duneau A, Pellequer Y, Lamprecht A. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J Control Release. 2012;161(1):50\u201361.","journal-title":"J Control Release"},{"key":"1256_CR47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejps.2018.04.026","volume":"120","author":"T Yang","year":"2018","unstructured":"Yang T, Ferrill L, Gallant L, McGillicuddy S, Fernandes T, Schields N, et al. Verapamil and riluzole cocktail liposomes overcome pharmacoresistance by inhibiting P-glycoprotein in brain endothelial and astrocyte cells: a potent approach to treat amyotrophic lateral sclerosis. Eur J Pharm Sci. 2018;120:30\u20139.","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"1256_CR48","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2217\/nnm-2017-0023","volume":"12","author":"MJ Gomes","year":"2017","unstructured":"Gomes MJ, Kennedy PJ, Martins S, Sarmento B. Delivery of siRNA silencing P-gp in peptide-functionalized nanoparticles causes efflux modulation at the blood\u2013brain barrier. Nanomedicine. 2017;12(12):1385\u201399.","journal-title":"Nanomedicine"},{"issue":"9","key":"1256_CR49","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.neurobiolaging.2015.05.020","volume":"36","author":"C Chiu","year":"2015","unstructured":"Chiu C, Miller MC, Monahan R, Osgood DP, Stopa EG, Silverberg GD. P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer\u2019s disease: preliminary observations. Neurobiol Aging. 2015;36(9):2475\u201382.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1256_CR50","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1080\/10717544.2017.1410256","volume":"24","author":"S-S Qi","year":"2017","unstructured":"Qi S-S, Sun J-H, Yu H-H, Yu S-Q. Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy. Drug deliv. 2017;24(1):1909\u201326.","journal-title":"Drug deliv"},{"issue":"1","key":"1256_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17425247.2016.1205583","volume":"14","author":"B Xiao","year":"2017","unstructured":"Xiao B, Ma L, Merlin D. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. Expert Opin Drug Deliv. 2017;14(1):65\u201373.","journal-title":"Expert Opin Drug Deliv"},{"key":"1256_CR52","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jconrel.2021.06.034","volume":"336","author":"Y Liang","year":"2021","unstructured":"Liang Y, Liu Z-Y, Wang P-Y, Li Y-J, Wang R-R, Xie S-Y. Nanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant. J Control Release. 2021;336:396\u2013409.","journal-title":"J Control Release"},{"key":"1256_CR53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.nantod.2017.12.007","volume":"18","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Feijen J, Zhong Z. Dual-targeted nanomedicines for enhanced tumor treatment. Nano Today. 2018;18:65\u201385.","journal-title":"Nano Today"},{"issue":"1","key":"1256_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12951-019-0562-3","volume":"18","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang F, Wen H, Shi W, Huang Q, Huang Y, et al. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis. J Nanobiotechnology. 2020;18(1):8.","journal-title":"J Nanobiotechnology"},{"issue":"6","key":"1256_CR55","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1021\/acsmedchemlett.0c00075","volume":"11","author":"V Sanna","year":"2020","unstructured":"Sanna V, Sechi M. Therapeutic potential of targeted nanoparticles and perspective on nanotherapies. ACS Med Chem Lett. 2020;11(6):1069\u201373.","journal-title":"ACS Med Chem Lett"},{"key":"1256_CR56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2015.10.019","volume":"98","author":"JA Kemp","year":"2016","unstructured":"Kemp JA, Shim MS, Heo CY, Kwon YJ. \u201cCombo\u201d nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv Drug Deliv Rev. 2016;98:3\u201318.","journal-title":"Adv Drug Deliv Rev"},{"issue":"22","key":"1256_CR57","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.1021\/acs.chemrev.7b00258","volume":"117","author":"W Fan","year":"2017","unstructured":"Fan W, Yung B, Huang P, Chen X. Nanotechnology for multimodal synergistic cancer therapy. Chem Rev. 2017;117(22):13566\u2013638.","journal-title":"Chem Rev"},{"issue":"3","key":"1256_CR58","doi-asserted-by":"publisher","first-page":"228","DOI":"10.20892\/j.issn.2095-3941.2017.0052","volume":"14","author":"Y Xin","year":"2017","unstructured":"Xin Y, Yin M, Zhao L, Meng F, Luo L. Recent progress on nanoparticle-based drug delivery systems for cancer therapy. Cancer Biol Med. 2017;14(3):228\u201341.","journal-title":"Cancer Biol Med"},{"issue":"9","key":"1256_CR59","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.trecan.2021.05.001","volume":"7","author":"BB Mendes","year":"2021","unstructured":"Mendes BB, Sousa DP, Conniot J, Conde J. Nanomedicine-based strategies to target and modulate the tumor microenvironment. Trends Cancer. 2021;7(9):847\u201362.","journal-title":"Trends Cancer"},{"issue":"1","key":"1256_CR60","doi-asserted-by":"publisher","first-page":"2103836","DOI":"10.1002\/advs.202103836","volume":"9","author":"S Peng","year":"2022","unstructured":"Peng S, Xiao F, Chen M, Gao H. Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci. 2022;9(1):2103836.","journal-title":"Adv Sci"},{"key":"1256_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2019.04.004","volume":"148","author":"K Liaw","year":"2019","unstructured":"Liaw K, Zhang Z, Kannan S. Neuronanotechnology for brain regeneration. Adv Drug Deliv Rev. 2019;148:3\u201318.","journal-title":"Adv Drug Deliv Rev"},{"key":"1256_CR62","doi-asserted-by":"crossref","unstructured":"Prasad EM, Hung SY. Current therapies in clinical trials of Parkinson's disease: a 2021 update. Pharmaceuticals (Basel). 2021;14(8).","DOI":"10.3390\/ph14080717"},{"key":"1256_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121427","volume":"283","author":"ED Carvalho","year":"2022","unstructured":"Carvalho ED, Morais MRG, Ferreira HP, Silva MMC, Guimar\u00e3es SC, P\u00eago AP. A paradigm shift: bioengineering meets mechanobiology towards overcoming remyelination failure. Biomaterials. 2022;283: 121427.","journal-title":"Biomaterials"},{"issue":"5","key":"1256_CR64","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1242\/dmm.030205","volume":"10","author":"AD Gitler","year":"2017","unstructured":"Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017;10(5):499\u2013502.","journal-title":"Dis Model Mech"},{"issue":"6","key":"1256_CR65","doi-asserted-by":"publisher","first-page":"886","DOI":"10.4103\/1673-5374.208546","volume":"12","author":"A Angelova","year":"2017","unstructured":"Angelova A, Angelov B. Dual and multi-drug delivery nanoparticles towards neuronal survival and synaptic repair. Neural Regen Res. 2017;12(6):886\u20139.","journal-title":"Neural Regen Res"},{"key":"1256_CR66","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.actbio.2018.03.030","volume":"72","author":"D Wu","year":"2018","unstructured":"Wu D, Zhang Y, Xu X, Guo T, Xie D, Zhu R, et al. RGD\/TAT-functionalized chitosan-graft-PEI-PEG gene nanovector for sustained delivery of NT-3 for potential application in neural regeneration. Acta Biomater. 2018;72:266\u201377.","journal-title":"Acta Biomater"},{"key":"1256_CR67","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.2147\/IJN.S164500","volume":"13","author":"W Pei","year":"2018","unstructured":"Pei W, Wan X, Shahzad KA, Zhang L, Song S, Jin X, et al. Direct modulation of myelin-autoreactive CD4(+) and CD8(+) T cells in EAE mice by a tolerogenic nanoparticle co-carrying myelin peptide-loaded major histocompatibility complexes, CD47 and multiple regulatory molecules. Int J Nanomed. 2018;13:3731\u201350.","journal-title":"Int J Nanomed"},{"issue":"43","key":"1256_CR68","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1016\/j.vaccine.2014.08.016","volume":"32","author":"G Cappellano","year":"2014","unstructured":"Cappellano G, Woldetsadik AD, Orilieri E, Shivakumar Y, Rizzi M, Carniato F, et al. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis. Vaccine. 2014;32(43):5681\u20139.","journal-title":"Vaccine"},{"issue":"2","key":"1256_CR69","doi-asserted-by":"publisher","first-page":"E156","DOI":"10.1073\/pnas.1408686111","volume":"112","author":"RA Maldonado","year":"2015","unstructured":"Maldonado RA, LaMothe RA, Ferrari JD, Zhang A-H, Rossi RJ, Kolte PN, et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci. 2015;112(2):E156\u201365.","journal-title":"Proc Natl Acad Sci"},{"issue":"18","key":"1256_CR70","doi-asserted-by":"publisher","first-page":"13853","DOI":"10.1021\/acs.jmedchem.1c01240","volume":"64","author":"Z Liu","year":"2021","unstructured":"Liu Z, Liu Q, Zhang B, Liu Q, Fang L, Gou S. Blood\u2013brain barrier permeable and no-releasing multifunctional nanoparticles for alzheimer\u2019s disease treatment: targeting NO\/cGMP\/CREB signaling pathways. J Med Chem. 2021;64(18):13853\u201372.","journal-title":"J Med Chem"},{"issue":"4","key":"1256_CR71","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3109\/08982104.2014.899369","volume":"24","author":"G Corace","year":"2014","unstructured":"Corace G, Angeloni C, Malaguti M, Hrelia S, Stein PC, Brandl M, et al. Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. J Liposome Res. 2014;24(4):323\u201335.","journal-title":"J Liposome Res"},{"key":"1256_CR72","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.msec.2018.05.062","volume":"91","author":"YC Kuo","year":"2018","unstructured":"Kuo YC, Tsai HC. Rosmarinic acid- and curcumin-loaded polyacrylamide-cardiolipin-poly(lactide-co-glycolide) nanoparticles with conjugated 83\u201314 monoclonal antibody to protect \u03b2-amyloid-insulted neurons. Mater Sci Eng, C Mater Biol Appl. 2018;91:445\u201357.","journal-title":"Mater Sci Eng, C Mater Biol Appl"},{"issue":"2","key":"1256_CR73","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11095-016-2080-4","volume":"34","author":"LP Guerzoni","year":"2017","unstructured":"Guerzoni LP, Nicolas V, Angelova A. In vitro modulation of TrkB receptor signaling upon sequential delivery of curcumin-DHA loaded carriers towards promoting neuronal survival. Pharm Res. 2017;34(2):492\u2013505.","journal-title":"Pharm Res"},{"issue":"1","key":"1256_CR74","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.biomaterials.2013.09.063","volume":"35","author":"C Zhang","year":"2014","unstructured":"Zhang C, Wan X, Zheng X, Shao X, Liu Q, Zhang Q, et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer\u2019s disease mice. Biomaterials. 2014;35(1):456\u201365.","journal-title":"Biomaterials"},{"issue":"2","key":"1256_CR75","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1021\/acsnano.7b07625","volume":"12","author":"Q Chen","year":"2018","unstructured":"Chen Q, Du Y, Zhang K, Liang Z, Li J, Yu H, et al. Tau-targeted multifunctional nanocomposite for combinational therapy of Alzheimer\u2019s disease. ACS Nano. 2018;12(2):1321\u201338.","journal-title":"ACS Nano"},{"issue":"12","key":"1256_CR76","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1021\/acschemneuro.6b00207","volume":"7","author":"P Kundu","year":"2016","unstructured":"Kundu P, Das M, Tripathy K, Sahoo SK. Delivery of dual drug loaded lipid based nanoparticles across the blood-brain barrier impart enhanced neuroprotection in a rotenone induced mouse model of Parkinson\u2019s disease. ACS Chem Neurosci. 2016;7(12):1658\u201370.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"1256_CR77","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12987-022-00315-1","volume":"19","author":"S Hernando","year":"2022","unstructured":"Hernando S, Nikolakopoulou P, Voulgaris D, Hernandez RM, Igartua M, Herland A. Dual effect of TAT functionalized DHAH lipid nanoparticles with neurotrophic factors in human BBB and microglia cultures. Fluids and Barriers of the CNS. 2022;19(1):22.","journal-title":"Fluids and Barriers of the CNS"},{"issue":"48","key":"1256_CR78","doi-asserted-by":"publisher","first-page":"56909","DOI":"10.1021\/acsami.1c16530","volume":"13","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Cheng A, Jia Y, Yang L, Ning Y, Xu L, et al. pH-Responsive multifunctional theranostic rapamycin-loaded nanoparticles for imaging and treatment of acute ischemic stroke. ACS Appl Mater Interfaces. 2021;13(48):56909\u201322.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"13","key":"1256_CR79","doi-asserted-by":"publisher","first-page":"15623","DOI":"10.1021\/acsami.2c00579","volume":"14","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Bao B, Li M, Tang Y. Bioactive composite nanoparticles for effective microenvironment regulation, neuroprotection, and cell differentiation. ACS Appl Mater Interfaces. 2022;14(13):15623\u201331.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1256_CR80","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jconrel.2016.04.038","volume":"233","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Jiang Y, Lv W, Wang Z, Lv L, Wang B, et al. Dual targeted nanocarrier for brain ischemic stroke treatment. Journal of controlled release\u202f: official journal of the Controlled Release Society. 2016;233:64\u201371.","journal-title":"Journal of controlled release : official journal of the Controlled Release Society"},{"key":"1256_CR81","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jconrel.2020.01.039","volume":"320","author":"Q Guo","year":"2020","unstructured":"Guo Q, Xu S, Yang P, Wang P, Lu S, Sheng D, et al. A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer\u2019s disease mice. Journal of controlled release\u202f: official journal of the Controlled Release Society. 2020;320:347\u201362.","journal-title":"Journal of controlled release : official journal of the Controlled Release Society"},{"issue":"8","key":"1256_CR82","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/iub.2330","volume":"72","author":"L Lv","year":"2020","unstructured":"Lv L, Yang F, Li H, Yuan J. Brain-targeted co-delivery of \u03b2-amyloid converting enzyme 1 shRNA and epigallocatechin-3-gallate by multifunctional nanocarriers for Alzheimer\u2019s disease treatment. IUBMB Life. 2020;72(8):1819\u201329.","journal-title":"IUBMB Life"},{"issue":"19","key":"1256_CR83","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.7150\/thno.28295","volume":"8","author":"Y Li","year":"2018","unstructured":"Li Y, Chen Z, Lu Z, Yang Q, Liu L, Jiang Z, et al. \u201cCell-addictive\u201d dual-target traceable nanodrug for Parkinson\u2019s disease treatment via flotillins pathway. Theranostics. 2018;8(19):5469\u201381.","journal-title":"Theranostics"},{"issue":"8","key":"1256_CR84","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1177\/0271678X16676826","volume":"37","author":"CY Xing","year":"2017","unstructured":"Xing CY, Tarumi T, Liu J, Zhang Y, Turner M, Riley J, et al. Distribution of cardiac output to the brain across the adult lifespan. J Cereb Blood Flow Metab. 2017;37(8):2848\u201356.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1256_CR85","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fphys.2019.00233","volume":"10","author":"AF Smith","year":"2019","unstructured":"Smith AF, Doyeux V, Berg M, Peyrounette M, Haft-Javaherian M, Larue AE, et al. Brain capillary networks across species: a few simple organizational requirements are sufficient to reproduce both structure and function. Front Physiol. 2019;10:233.","journal-title":"Front Physiol"},{"issue":"9","key":"1256_CR86","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41573-020-0072-x","volume":"19","author":"SC Cunnane","year":"2020","unstructured":"Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19(9):609\u201333.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1256_CR87","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1124\/pharmrev.121.000418","volume":"74","author":"I Gallego","year":"2022","unstructured":"Gallego I, Villate-Beitia I, Saenz-Del-Burgo L, Puras G, Pedraz JL. Therapeutic opportunities and delivery strategies for brain revascularization in stroke, neurodegeneration, and aging. Pharmacol Rev. 2022;74(2):439\u201361.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"1256_CR88","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00004647-200404000-00001","volume":"24","author":"B Schaller","year":"2004","unstructured":"Schaller B, Graf R. Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy. J Cereb Blood Flow Metab. 2004;24(4):351\u201371.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"1256_CR89","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00004647-199904000-00001","volume":"19","author":"G Fiskum","year":"1999","unstructured":"Fiskum G, Murphy AN, Beal MF. Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases. J Cereb Blood Flow Metab. 1999;19(4):351\u201369.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"6","key":"1256_CR90","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1227\/NEU.0b013e31824d179b","volume":"70","author":"M Laroche","year":"2012","unstructured":"Laroche M, Kutcher ME, Huang MC, Cohen MJ, Manley GT. Coagulopathy after traumatic brain injury. Neurosurgery. 2012;70(6):1334\u201345.","journal-title":"Neurosurgery"},{"issue":"2","key":"1256_CR91","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/1570161115666161104095522","volume":"15","author":"D Radak","year":"2017","unstructured":"Radak D, Katsiki N, Resanovic I, Jovanovic A, Sudar-Milovanovic E, Zafirovic S, et al. Apoptosis and acute brain ischemia in ischemic stroke. Curr Vasc Pharmacol. 2017;15(2):115\u201322.","journal-title":"Curr Vasc Pharmacol"},{"issue":"2","key":"1256_CR92","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5853\/jos.2019.02978","volume":"22","author":"MHH Balch","year":"2020","unstructured":"Balch MHH, Nimjee SM, Rink C, Hannawi Y. Beyond the brain: the systemic pathophysiological response to acute ischemic stroke. J Stroke. 2020;22(2):159\u201372.","journal-title":"J Stroke"},{"issue":"3","key":"1256_CR93","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1161\/CIRCRESAHA.116.309278","volume":"120","author":"L Catanese","year":"2017","unstructured":"Catanese L, Tarsia J, Fisher M. Acute ischemic stroke therapy overview. Circ Res. 2017;120(3):541\u201358.","journal-title":"Circ Res"},{"issue":"10029","key":"1256_CR94","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","volume":"387","author":"M Goyal","year":"2016","unstructured":"Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723\u201331.","journal-title":"Lancet"},{"issue":"18","key":"1256_CR95","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1007\/s00018-014-1625-0","volume":"71","author":"M Vallon","year":"2014","unstructured":"Vallon M, Chang J, Zhang H, Kuo CJ. Developmental and pathological angiogenesis in the central nervous system. Cell Mol Life Sci. 2014;71(18):3489\u2013506.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1256_CR96","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/1673-5374.264442","volume":"15","author":"M Hatakeyama","year":"2020","unstructured":"Hatakeyama M, Ninomiya I, Kanazawa M. Angiogenesis and neuronal remodeling after ischemic stroke. Neural Regen Res. 2020;15(1):16\u20139.","journal-title":"Neural Regen Res"},{"issue":"12","key":"1256_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202100028","volume":"10","author":"H Yang","year":"2021","unstructured":"Yang H, Luo Y, Hu H, Yang S, Li Y, Jin H, et al. pH-sensitive, cerebral vasculature-targeting hydroxyethyl starch functionalized nanoparticles for improved angiogenesis and neurological function recovery in ischemic stroke. Adv Healthc Mater. 2021;10(12): e2100028.","journal-title":"Adv Healthc Mater"},{"issue":"Suppl 1","key":"1256_CR98","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.3727\/096368914X684998","volume":"23","author":"R Ju","year":"2014","unstructured":"Ju R, Wen Y, Gou R, Wang Y, Xu Q. The experimental therapy on brain ischemia by improvement of local angiogenesis with tissue engineering in the mouse. Cell Transplant. 2014;23(Suppl 1):S83-95.","journal-title":"Cell Transplant"},{"issue":"11","key":"1256_CR99","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.1021\/acsbiomaterials.9b01362","volume":"5","author":"L Deng","year":"2019","unstructured":"Deng L, Zhang F, Wu Y, Luo J, Mao X, Long L, et al. RGD-modified nanocarrier-mediated targeted delivery of HIF-1\u03b1-AA plasmid DNA to cerebrovascular endothelial cells for ischemic stroke treatment. ACS Biomater Sci Eng. 2019;5(11):6254\u201364.","journal-title":"ACS Biomater Sci Eng"},{"issue":"15","key":"1256_CR100","doi-asserted-by":"publisher","first-page":"8126","DOI":"10.1039\/C5NR09077F","volume":"8","author":"R Ferreira","year":"2016","unstructured":"Ferreira R, Fonseca MC, Santos T, Sargento-Freitas J, Tjeng R, Paiva F, et al. Retinoic acid-loaded polymeric nanoparticles enhance vascular regulation of neural stem cell survival and differentiation after ischaemia. Nanoscale. 2016;8(15):8126\u201337.","journal-title":"Nanoscale"},{"issue":"9","key":"1256_CR101","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1161\/01.STR.25.9.1794","volume":"25","author":"J Krupinski","year":"1994","unstructured":"Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke. 1994;25(9):1794\u20138.","journal-title":"Stroke"},{"key":"1256_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.652647","volume":"15","author":"H Zhu","year":"2021","unstructured":"Zhu H, Zhang Y, Zhong Y, Ye Y, Hu X, Gu L, et al. Inflammation-mediated angiogenesis in ischemic stroke. Front Cell Neurosci. 2021;15: 652647.","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"1256_CR103","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1177\/0271678X19834158","volume":"39","author":"M Kanazawa","year":"2019","unstructured":"Kanazawa M, Takahashi T, Ishikawa M, Onodera O, Shimohata T, Del Zoppo GJ. Angiogenesis in the ischemic core: a potential treatment target? J Cereb Blood Flow Metab. 2019;39(5):753\u201369.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"10","key":"1256_CR104","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1002\/jnr.23088","volume":"90","author":"Y Ma","year":"2012","unstructured":"Ma Y, Zechariah A, Qu Y, Hermann DM. Effects of vascular endothelial growth factor in ischemic stroke. J Neurosci Res. 2012;90(10):1873\u201382.","journal-title":"J Neurosci Res"},{"issue":"18","key":"1256_CR105","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.7150\/thno.27466","volume":"8","author":"M Li","year":"2018","unstructured":"Li M, Liu Y, Chen J, Liu T, Gu Z, Zhang J, et al. Platelet bio-nanobubbles as microvascular recanalization nanoformulation for acute ischemic stroke lesion theranostics. Theranostics. 2018;8(18):4870\u201383.","journal-title":"Theranostics"},{"issue":"2","key":"1256_CR106","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1021\/acsnano.9b08587","volume":"14","author":"M Li","year":"2020","unstructured":"Li M, Li J, Chen J, Liu Y, Cheng X, Yang F, et al. Platelet membrane biomimetic magnetic nanocarriers for targeted delivery and in situ generation of nitric oxide in early ischemic stroke. ACS Nano. 2020;14(2):2024\u201335.","journal-title":"ACS Nano"},{"issue":"5","key":"1256_CR107","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202000044","volume":"4","author":"S Bersini","year":"2020","unstructured":"Bersini S, Arrojo EDR, Huang L, Shokhirev MN, Hetzer MW. Transcriptional and functional changes of the human microvasculature during physiological aging and Alzheimer disease. Adv Biosyst. 2020;4(5): e2000044.","journal-title":"Adv Biosyst"},{"key":"1256_CR108","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.brainres.2011.04.049","volume":"1398","author":"S Garbuzova-Davis","year":"2011","unstructured":"Garbuzova-Davis S, Rodrigues MC, Hernandez-Ontiveros DG, Louis MK, Willing AE, Borlongan CV, et al. Amyotrophic lateral sclerosis: a neurovascular disease. Brain Res. 2011;1398:113\u201325.","journal-title":"Brain Res"},{"issue":"10004","key":"1256_CR109","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/S0140-6736(15)00463-8","volume":"386","author":"JT O'Brien","year":"2015","unstructured":"O\u2019Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698\u2013706.","journal-title":"Lancet"},{"issue":"2","key":"1256_CR110","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc724","volume":"2","author":"E Ruoslahti","year":"2002","unstructured":"Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002;2(2):83\u201390.","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"1256_CR111","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMcibr1309402","volume":"369","author":"S Das","year":"2013","unstructured":"Das S, Marsden PA. Angiogenesis in glioblastoma. N Engl J Med. 2013;369(16):1561\u20133.","journal-title":"N Engl J Med"},{"key":"1256_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.622615","volume":"12","author":"J Guyon","year":"2021","unstructured":"Guyon J, Chapouly C, Andrique L, Bikfalvi A, Daubon T. The Normal and brain tumor vasculature: morphological and functional characteristics and therapeutic targeting. Front Physiol. 2021;12: 622615.","journal-title":"Front Physiol"},{"issue":"9","key":"1256_CR113","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1007\/s12035-019-1561-y","volume":"56","author":"JR Kane","year":"2019","unstructured":"Kane JR. The role of brain vasculature in glioblastoma. Mol Neurobiol. 2019;56(9):6645\u201353.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"1256_CR114","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11060-017-2477-x","volume":"133","author":"RJ Diaz","year":"2017","unstructured":"Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ. The role of bevacizumab in the treatment of glioblastoma. J Neurooncol. 2017;133(3):455\u201367.","journal-title":"J Neurooncol"},{"issue":"25","key":"1256_CR115","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.2015.61.5005","volume":"33","author":"T Sandmann","year":"2015","unstructured":"Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol. 2015;33(25):2735\u201344.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1256_CR116","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-14-0834","volume":"20","author":"TT Batchelor","year":"2014","unstructured":"Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014;20(22):5612\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1256_CR117","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.molmed.2015.01.001","volume":"21","author":"X Xu","year":"2015","unstructured":"Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med. 2015;21(4):223\u201332.","journal-title":"Trends Mol Med"},{"issue":"7","key":"1256_CR118","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell. 2017;171(7):1678-91.e13.","journal-title":"Cell"},{"issue":"20","key":"1256_CR119","first-page":"7501","volume":"61","author":"L Bello","year":"2001","unstructured":"Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 2001;61(20):7501\u20136.","journal-title":"Cancer Res"},{"issue":"3","key":"1256_CR120","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.7150\/thno.38147","volume":"10","author":"M Zhao","year":"2020","unstructured":"Zhao M, van Straten D, Broekman MLD, Pr\u00e9at V, Schiffelers RM. Nanocarrier-based drug combination therapy for glioblastoma. Theranostics. 2020;10(3):1355\u201372.","journal-title":"Theranostics"},{"issue":"2","key":"1256_CR121","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4155\/tde.10.13","volume":"1","author":"CM Hu","year":"2010","unstructured":"Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv. 2010;1(2):323\u201334.","journal-title":"Ther Deliv"},{"issue":"19","key":"1256_CR122","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1016\/j.biomaterials.2014.03.017","volume":"35","author":"ZZ Yang","year":"2014","unstructured":"Yang ZZ, Li JQ, Wang ZZ, Dong DW, Qi XR. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014;35(19):5226\u201339.","journal-title":"Biomaterials"},{"key":"1256_CR123","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2147\/IJN.S124593","volume":"12","author":"YY Tseng","year":"2017","unstructured":"Tseng YY, Yang TC, Wang YC, Lee WH, Chang TM, Kau YC, et al. Targeted concurrent and sequential delivery of chemotherapeutic and antiangiogenic agents to the brain by using drug-loaded nanofibrous membranes. Int J Nanomedicine. 2017;12:1265\u201376.","journal-title":"Int J Nanomedicine"},{"key":"1256_CR124","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jconrel.2018.04.021","volume":"279","author":"E Choi","year":"2018","unstructured":"Choi E, Oh J, Lee D, Lee J, Tan X, Kim M, et al. A ternary-complex of a suicide gene, a RAGE-binding peptide, and polyethylenimine as a gene delivery system with anti-tumor and anti-angiogenic dual effects in glioblastoma. J Control Release. 2018;279:40\u201352.","journal-title":"J Control Release"},{"key":"1256_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.812916","volume":"11","author":"S Jain","year":"2021","unstructured":"Jain S, Chalif EJ, Aghi MK. Interactions between anti-angiogenic therapy and immunotherapy in glioblastoma. Front Oncol. 2021;11: 812916.","journal-title":"Front Oncol"},{"issue":"1","key":"1256_CR126","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4049\/jimmunol.174.1.215","volume":"174","author":"MM Dikov","year":"2005","unstructured":"Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol. 2005;174(1):215\u201322.","journal-title":"J Immunol"},{"key":"1256_CR127","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canlet.2020.09.028","volume":"496","author":"H Wang","year":"2021","unstructured":"Wang H, Zhou H, Xu J, Lu Y, Ji X, Yao Y, et al. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy. Cancer Lett. 2021;496:134\u201343.","journal-title":"Cancer Lett"},{"issue":"1","key":"1256_CR128","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12032-019-1329-2","volume":"37","author":"R Tamura","year":"2019","unstructured":"Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol. 2019;37(1):2.","journal-title":"Med Oncol"},{"issue":"4","key":"1256_CR129","first-page":"240","volume":"10","author":"JD Hainsworth","year":"2012","unstructured":"Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT, Spigel DR. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab\/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol. 2012;10(4):240\u20136.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"1256_CR130","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2217\/cns-2015-0010","volume":"5","author":"Y Odia","year":"2016","unstructured":"Odia Y, Sul J, Shih JH, Kreisl TN, Butman JA, Iwamoto FM, et al. A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma. CNS Oncol. 2016;5(2):59\u201367.","journal-title":"CNS Oncol"},{"issue":"4","key":"1256_CR131","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","volume":"27","author":"L Nayak","year":"2021","unstructured":"Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, et al. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. Clin Cancer Res. 2021;27(4):1048\u201357.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1256_CR132","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s13311-015-0407-1","volume":"13","author":"DN Renner","year":"2016","unstructured":"Renner DN, Malo CS, Jin F, Parney IF, Pavelko KD, Johnson AJ. Improved treatment efficacy of antiangiogenic therapy when combined with picornavirus vaccination in the GL261 glioma model. Neurotherapeutics. 2016;13(1):226\u201336.","journal-title":"Neurotherapeutics"},{"key":"1256_CR133","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fimmu.2016.00052","volume":"7","author":"S Romero-Garcia","year":"2016","unstructured":"Romero-Garcia S, Moreno-Altamirano MM, Prado-Garcia H, S\u00e1nchez-Garc\u00eda FJ. Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol. 2016;7:52.","journal-title":"Front Immunol"},{"issue":"61","key":"1256_CR134","doi-asserted-by":"publisher","first-page":"103657","DOI":"10.18632\/oncotarget.21761","volume":"8","author":"V Miranda-Gon\u00e7alves","year":"2017","unstructured":"Miranda-Gon\u00e7alves V, Cardoso-Carneiro D, Valbom I, Cury FP, Silva VA, Granja S, et al. Metabolic alterations underlying bevacizumab therapy in glioblastoma cells. Oncotarget. 2017;8(61):103657\u201370.","journal-title":"Oncotarget"},{"issue":"1","key":"1256_CR135","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10456-019-09698-6","volume":"23","author":"EA Kuczynski","year":"2020","unstructured":"Kuczynski EA, Reynolds AR. Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis. 2020;23(1):55\u201374.","journal-title":"Angiogenesis"},{"issue":"Pt 4","key":"1256_CR136","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/brain\/awq044","volume":"133","author":"S El Hallani","year":"2010","unstructured":"El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain. 2010;133(Pt 4):973\u201382.","journal-title":"Brain"},{"issue":"37","key":"1256_CR137","doi-asserted-by":"publisher","first-page":"12950","DOI":"10.1523\/JNEUROSCI.2017-12.2012","volume":"32","author":"S Scully","year":"2012","unstructured":"Scully S, Francescone R, Faibish M, Bentley B, Taylor SL, Oh D, et al. Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J Neurosci. 2012;32(37):12950\u201360.","journal-title":"J Neurosci"},{"key":"1256_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173692","volume":"891","author":"R Smolarczyk","year":"2021","unstructured":"Smolarczyk R, Czapla J, Jarosz-Biej M, Czerwinski K, Cicho\u0144 T. Vascular disrupting agents in cancer therapy. Eur J Pharmacol. 2021;891: 173692.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1256_CR139","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1021\/acs.nanolett.1c00168","volume":"21","author":"B Li","year":"2021","unstructured":"Li B, Chu T, Wei J, Zhang Y, Qi F, Lu Z, et al. Platelet-membrane-coated nanoparticles enable vascular disrupting agent combining anti-angiogenic drug for improved tumor vessel impairment. Nano Lett. 2021;21(6):2588\u201395.","journal-title":"Nano Lett"},{"issue":"1","key":"1256_CR140","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13073-018-0588-4","volume":"10","author":"SL Bucktrout","year":"2018","unstructured":"Bucktrout SL, Bluestone JA, Ramsdell F. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Medicine. 2018;10(1):79.","journal-title":"Genome Medicine"},{"issue":"11","key":"1256_CR141","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1256_CR142","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2020","unstructured":"Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer. 2020;20(1):12\u201325.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1256_CR143","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13046-022-02251-2","volume":"41","author":"M Bausart","year":"2022","unstructured":"Bausart M, Pr\u00e9at V, Malfanti A. Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res. 2022;41(1):35.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6472","key":"1256_CR144","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1126\/science.aay0479","volume":"366","author":"J Rustenhoven","year":"2019","unstructured":"Rustenhoven J, Kipnis J. Bypassing the blood-brain barrier. Science. 2019;366(6472):1448\u20139.","journal-title":"Science"},{"issue":"7612","key":"1256_CR145","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nature18626","volume":"535","author":"AJ Filiano","year":"2016","unstructured":"Filiano AJ, Xu Y, Tustison NJ, Marsh RL, Baker W, Smirnov I, et al. Unexpected role of interferon-\u03b3 in regulating neuronal connectivity and social behaviour. Nature. 2016;535(7612):425\u20139.","journal-title":"Nature"},{"issue":"7590","key":"1256_CR146","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nature16939","volume":"530","author":"C Schl\u00e4ger","year":"2016","unstructured":"Schl\u00e4ger C, K\u00f6rner H, Krueger M, Vidoli S, Haberl M, Mielke D, et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature. 2016;530(7590):349\u201353.","journal-title":"Nature"},{"key":"1256_CR147","doi-asserted-by":"crossref","unstructured":"Guse K, Hagemann N, Thiele L, Remlinger J, Salmen A, Hoepner R, et al. CNS Antigen-specific neuroinflammation attenuates ischemic stroke with involvement of polarized myeloid cells. Neurol Neuroimmunol Neuroinflamm. 2022;9(4).","DOI":"10.1212\/NXI.0000000000001168"},{"key":"1256_CR148","doi-asserted-by":"crossref","unstructured":"Gowd V, Ahmad A, Tarique M, Suhail M, Zughaibi TA, Tabrez S, et al. Advancement of cancer immunotherapy using nanoparticles-based nanomedicine.\u00a0Semin Cancer Biol. 2022.","DOI":"10.1016\/j.semcancer.2022.03.026"},{"issue":"1","key":"1256_CR149","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1038\/s41467-019-11719-3","volume":"10","author":"A Galstyan","year":"2019","unstructured":"Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, et al. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat Commun. 2019;10(1):3850.","journal-title":"Nat Commun"},{"issue":"2","key":"1256_CR150","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.ijpharm.2015.09.062","volume":"495","author":"G Lollo","year":"2015","unstructured":"Lollo G, Vincent M, Ullio-Gamboa G, Lemaire L, Franconi F, Couez D, et al. Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. Int J Pharm. 2015;495(2):972\u201380.","journal-title":"Int J Pharm"},{"issue":"18","key":"1256_CR151","doi-asserted-by":"publisher","first-page":"1705054","DOI":"10.1002\/adma.201705054","volume":"30","author":"C Qiao","year":"2018","unstructured":"Qiao C, Yang J, Shen Q, Liu R, Li Y, Shi Y, et al. Traceable nanoparticles with dual targeting and ROS response for RNAi-based immunochemotherapy of intracranial glioblastoma treatment. Adv Mater. 2018;30(18):1705054.","journal-title":"Adv Mater"},{"issue":"1","key":"1256_CR152","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1080\/10717544.2018.1509907","volume":"25","author":"Z Sun","year":"2018","unstructured":"Sun Z, Zhang Y, Cao D, Wang X, Yan X, Li H, et al. PD-1\/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer. Drug Delivery. 2018;25(1):1746\u201355.","journal-title":"Drug Delivery"},{"issue":"10","key":"1256_CR153","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1039\/C7SC04853J","volume":"9","author":"P Zhao","year":"2018","unstructured":"Zhao P, Wang Y, Kang X, Wu A, Yin W, Tang Y, et al. Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy. Chem Sci. 2018;9(10):2674\u201389.","journal-title":"Chem Sci"},{"issue":"2","key":"1256_CR154","first-page":"1365","volume":"13","author":"P Kadiyala","year":"2019","unstructured":"Kadiyala P, Li D, Nu\u00f1ez FM, Altshuler D, Doherty R, Kuai R, et al. High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano. 2019;13(2):1365\u201384.","journal-title":"ACS Nano"},{"issue":"2","key":"1256_CR155","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/ijms19020594","volume":"19","author":"B Montico","year":"2018","unstructured":"Montico B, Nigro A, Casolaro V, Dal Col J. Immunogenic apoptosis as a novel tool for anticancer vaccine development. Int J Mol Sci. 2018;19(2):594.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"1256_CR156","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1158\/1078-0432.CCR-20-0341","volume":"26","author":"L Scheetz","year":"2020","unstructured":"Scheetz L, Kadiyala P, Sun X, Son S, Hassani Najafabadi A, Aikins M, et al. Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas. Clin Cancer Res. 2020;26(16):4369\u201380.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1256_CR157","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","volume":"23","author":"JE Kim","year":"2017","unstructured":"Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, et al. Combination therapy with Anti-PD-1, Anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res. 2017;23(1):124\u201336.","journal-title":"Clin Cancer Res"},{"key":"1256_CR158","doi-asserted-by":"crossref","unstructured":"Bhagavati S. Autoimmune disorders of the nervous system: pathophysiology, clinical features, and therapy.\u00a0Front\u00a0Neurol. 2021;12.","DOI":"10.3389\/fneur.2021.664664"},{"issue":"2","key":"1256_CR159","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/19714009211042879","volume":"35","author":"G Shadmani","year":"2021","unstructured":"Shadmani G, Simkins TJ, Assadsangabi R, Apperson M, Hacein-Bey L, Raslan O, et al. Autoimmune diseases of the brain, imaging and clinical review. Neuroradiol J. 2021;35(2):152\u201369.","journal-title":"Neuroradiol J"},{"key":"1256_CR160","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jconrel.2022.02.009","volume":"343","author":"N Rahiman","year":"2022","unstructured":"Rahiman N, Mohammadi M, Alavizadeh SH, Arabi L, Badiee A, Jaafari MR. Recent advancements in nanoparticle-mediated approaches for restoration of multiple sclerosis. J Control Release. 2022;343:620\u201344.","journal-title":"J Control Release"},{"issue":"28","key":"1256_CR161","doi-asserted-by":"publisher","first-page":"11270","DOI":"10.1073\/pnas.1120611109","volume":"109","author":"A Yeste","year":"2012","unstructured":"Yeste A, Nadeau M, Burns Evan J, Weiner Howard L, Quintana FJ. Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci. 2012;109(28):11270\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"50","key":"1256_CR162","doi-asserted-by":"publisher","first-page":"32017","DOI":"10.1073\/pnas.2016451117","volume":"117","author":"E Kenison Jessica","year":"2020","unstructured":"Kenison Jessica E, Jhaveri A, Li Z, Khadse N, Tjon E, Tezza S, et al. Tolerogenic nanoparticles suppress central nervous system inflammation. Proc Natl Acad Sci. 2020;117(50):32017\u201328.","journal-title":"Proc Natl Acad Sci"},{"issue":"16","key":"1256_CR163","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.2217\/nnm-2020-0102","volume":"15","author":"X Feng","year":"2020","unstructured":"Feng X, Liu J, Xu W, Li G, Ding J. Tackling autoimmunity with nanomedicines. Nanomedicine. 2020;15(16):1585\u201397.","journal-title":"Nanomedicine"},{"issue":"2","key":"1256_CR164","first-page":"E156","volume":"112","author":"A Maldonado Roberto","year":"2015","unstructured":"Maldonado Roberto A, LaMothe RA, Ferrari Joseph D, Zhang A-H, Rossi Robert J, Kolte Pallavi N, et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci. 2015;112(2):E156\u201365.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1256_CR165","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drudis.2019.09.017","volume":"25","author":"M Norouzi","year":"2020","unstructured":"Norouzi M, Amerian M, Amerian M, Atyabi F. Clinical applications of nanomedicine in cancer therapy. Drug Discov Today. 2020;25(1):107\u201325.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1256_CR166","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1256_CR167","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","volume":"12","author":"S \u0110or\u0111evi\u0107","year":"2022","unstructured":"\u0110or\u0111evi\u0107 S, Gonzalez MM, Conejos-S\u00e1nchez I, Carreira B, Pozzi S, Ac\u00farcio RC, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500\u201325.","journal-title":"Drug Deliv Transl Res"},{"issue":"12","key":"1256_CR168","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1039\/D0TB02957B","volume":"9","author":"F Persano","year":"2021","unstructured":"Persano F, Batasheva S, Fakhrullina G, Gigli G, Leporatti S, Fakhrullin R. Recent advances in the design of inorganic and nano-clay particles for the treatment of brain disorders. J Mater Chem B. 2021;9(12):2756\u201384.","journal-title":"J Mater Chem B"},{"issue":"8","key":"1256_CR169","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/molecules25081929","volume":"25","author":"SU Islam","year":"2020","unstructured":"Islam SU, Shehzad A, Ahmed MB, Lee YS. Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders. Molecules (Basel, Switzerland). 2020;25(8):1929.","journal-title":"Molecules (Basel, Switzerland)"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01256-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-022-01256-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01256-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T11:16:34Z","timestamp":1701342994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-022-01256-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":169,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1256"],"URL":"https:\/\/doi.org\/10.1007\/s13346-022-01256-w","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"30 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}